Syndecan-1 as a Biomarker for Cardiovascular Risk in Patients with Behçet’s Disease

Q: What was the purpose of measuring syndecan-1 in this study?

The study assessed whether syndecan-1 levels could function as a biomarker to help diagnose cardiovascular diseases and atherosclerosis in patients with Behçet’s disease.

Q: How were participants and key measurements arranged?

Fifty-six patients with Behçet’s disease and 56 age- and sex-matched controls were enrolled. cIMT was measured by a single radiologist, and syndecan-1 was determined by ELISA.

Q: What did the results show about syndecan-1 and cIMT?

Syndecan-1 levels and cIMT were significantly higher in patients than in controls. Correlation analysis found a significant negative relationship between syndecan-1 and cIMT, and regression linked cIMT with age, syndecan-1, and LDL.

Q: What conclusion did the authors draw and what are the next steps?

Syndecan-1 was higher in patients and increased syndecan-1 may slow subclinical atherosclerosis progression. The study is preliminary, and further detailed research is needed.

Sep 28, 2026

Uploaded by Dipper

Study evaluates whether syndecan-1 levels can serve as a biomarker for diagnosing cardiovascular disease and atherosclerosis in patients with Behçet’s disease. After sample-size estimation, 56 patients and 56 age- and sex-matched controls were enrolled. Carotid intima-media thickness (cIMT) was measured by a single radiologist, and syndecan-1 was quantified using a human ELISA kit. Patients showed higher syndecan-1 and cIMT, with a negative association between syndecan-1 and cIMT, suggesting potential relevance to subclinical atherosclerosis progression.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages8

Reading Time20 min

AccessFree to download

Abstract

Introduction

Materials and Methods

Results

Conclusion

ORIGINAL ARTICLE Archives of Rheumatology 2025;40(4):435-442 DOI: 10.5152/ArchRheumatol.2025.11178 Syndecan-1 as a Biomarker for Cardiovascular Risk in Patients with Behçet’s Disease ABSTRACT Background/Aims: This study aimed to assess the potential of syndecan-1 levels as a biomarker for diagnosing cardiovascular diseases and atherosclerosis in patients with Behçet’s disease. Materials and Methods: After estimating the required sample size, 56 patients with Behçet’s disease and 56 age- and sex-matched controls were enrolled in the study. Carotid intima-media thickness (cIMT) was measured by a single radiologist using an appropriate technique. Syndecan-1 levels were determined with an Syndecan-1 human ELISA kit (CLOUD CLONE, USCN) . The test system showed a correlation coefficient of 0.99 between expected and actual values, with a detection limit of around 0.01 ng/mL. The intra-assay coefficient of variation (CV) was under 10%, and the inter-assay CV was under 12% . Results: The data obtained from the study showed that syndecan-1 levels (P < .002) and cIMT measurements (P < .015) were significantly higher in patients with Behçet’s disease compared to the healthy control group. Additionally, correlation analysis revealed a significant negative relationship between syndecan-1 levels and cIMT. In a stepwise multiple regression analysis, a strong independent relationship was found between cIMT and age (beta [β] = 0.474, P < .001), syndecan-1 (β = 0.302, P = .007), and low-density lipoprotein (β = 0.219, P = .050) . Conclusion: Syndecan-1 levels were higher in patients with Behçet’s disease compared to controls, and increased syndecan-1 may slow the progression of subclinical atherosclerosis. This study is a preliminary investigation. Further detailed studies are needed. Keywords: Atherosclerosis, Behçet di̇sease, cardiovascular risk, sydecan-1, cIMT Introduction Behçet’s disease is a chronic autoimmune disorder characterized by systemic inflammation, with an unclear etiology and a tendency for vascular involvement. Although it mainly affects the blood vessels, it can also involve multiple organ systems. Key clinical symptoms include eye problems, recurrent mouth ulcers, inflammation of both arteries and veins, arthritis, skin lesions, as well as gastrointestinal and neurological issues.1,2 In patients with Behçet’s disease, an overactive immune response causes widespread systemic inflammatory damage.3 The condition is more common in men than in women and generally follows a more severe course in male patients. It occurs more often in countries along the historic Silk Road, especially in the Middle East and East Asia. Its prevalence in Asian populations ranges from 110 to 120 per 100 000,1,2 Copyright@Author(s) -[Available online at archivesof rheumatology.com](Available online at archivesof rheumatology.com). Content of this journal is licensed under a Creative Commons Attribution (CC BY) 4.0 International License. Cengiz Kadıyoran1 Pınar Diydem Yılmaz1 Mevlüt Hakan Göktepe2 Adem Küçük3 Mustafa Oğul4 Erkan Cüre5 Faik Özdengül6 1Department of Radiology, Necmettin Erbakan University Medical School, Konya, Türkiye 2Department of Internal Medicine, Necmettin Erbakan University Medical School, Konya, Türkiye 3Department of Rheumatology, Necmettin Erbakan University Medical School, Konya, Türkiye 4Department of Internal Medicine, Konya Numune Hospital, Konya, Türkiye 5Department of Internal Medicine, Gaziosmanpaşa Medicalpark Hospital, İstinye University, İstanbul, Türkiye 6Department of Physiology, Necmettin Erbakan University Medical School, Konya, Türkiye Corresponding author: Cengiz Kadiyoran 􀀍 [ckadiyoran@hotmail.com](ckadiyoran@hotmail.com) Received: March 27, 2025 Revision Requested: June 16, 2025 Last Revision Received: September 9, 2025 Accepted: September 15, 2025 Publication Date: December 1, 2025 Cite this article as: Kadiyoran C, Diydem Yilmaz P, Hakan Göktepe M, et al. Syndec

FAQs

What was the purpose of measuring syndecan-1 in this study?

The study assessed whether syndecan-1 levels could function as a biomarker to help diagnose cardiovascular diseases and atherosclerosis in patients with Behçet’s disease.

How were participants and key measurements arranged?

Fifty-six patients with Behçet’s disease and 56 age- and sex-matched controls were enrolled. cIMT was measured by a single radiologist, and syndecan-1 was determined by ELISA.

What did the results show about syndecan-1 and cIMT?

Syndecan-1 levels and cIMT were significantly higher in patients than in controls. Correlation analysis found a significant negative relationship between syndecan-1 and cIMT, and regression linked cIMT with age, syndecan-1, and LDL.

What conclusion did the authors draw and what are the next steps?

Syndecan-1 was higher in patients and increased syndecan-1 may slow subclinical atherosclerosis progression. The study is preliminary, and further detailed research is needed.

Sep 28, 2026

Uploaded by Dipper